


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Michel Pairet et al
Serial No. : 10/086,145
Filed : October 19, 2001
For : Pharmaceutical Compositions Based on Anticholinergics and
Corticosteroids

Assistant Commissioner for Patents
Washington, D.C. 20231

) Art Unit: 1614
) Examiner: to be assigned
) Docket No.: 1/1174



RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

SUPPLEMENTAL TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Sir:

COPY OF PAPERS
ORIGINALLY FILED

Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and

1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

_triplicate copies of this form are enclosed.

Respectfully submitted,

Timothy X. Witkowski
Attorney for Applicant(s)
Reg. No. 40,232

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877
Tel.: (203) 798-4310
Docket No.: 1/1174

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, DC 20231

on June 11, 2002

By: Timothy X. Witkowski
Reg. No. 40,232

DUPLICATE